Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
NEW YORK, May 19, 2017 -- Safirstein Metcalf LLP announces that a class action lawsuit has been filed against Neurotrope, Inc. (“Neurotrope” or the “Company”) (NASDAQ:NTRP) in the United States District Court for the Southern District of New York, and is filed on behalf of a class consisting of all persons or entities who acquired shares of Neurotrope between January 7, 2016, and April 28, 2017 (the "Class Period").
If you purchased Neurotrope securities during the Class Period, and would like more information about getting involved in the Neurotrope Shareholder Class Action, please call 1-800-221-0015, or email [email protected]. If you wish to serve as lead plaintiff, you must move the Court no later than July 17, 2017.
A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member
The complaint alleges that, throughout the class period, Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” However, the underlying trial data contradicts these representations, as the top-line data relating to the 20 microgram dose of Bryostatin-1 failed to produce results that were statistically significant. In addition, Neurotrope failed to disclose statements regarding the efficacy of the 40 microgram dose with regard to its primary and secondary endpoints. Upon this news, shares of Neurotrope fell from a close of $18.81 on April 28, 2017, to a close of $6.97 per share on May 1, 2017.
About Safirstein Metcalf LLP
Safirstein Metcalf LLP focuses its practice on shareholder rights. The law firm also practices in the areas of antitrust and consumer protection. All of the Firm’s legal endeavors are rooted in its core mission: provide investor and consumer protection.
Attorney advertising. Prior results do not guarantee a similar outcome.
Safirstein Metcalf LLP Peter Safirstein, Esq. 1250 Broadway 27th Floor New York, NY 10001 1-800-221-0015
